Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 ...

To determine the optimum bile acid regimen for rapid gall stone dissolution, 48 gall stone patients were divided into four groups of 12 according to stone diameter and were randomly allocated to ...

Ipsen announces Bylvay data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS: Paris, France Tuesday, November 19, 2024, 11:00 H ...

Data supports the safety profile in the ASSERT clinical trial ... PFIC is a group of rare genetic disorders in which bile acids build up in the liver, causing damage, which may result in liver ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 ...

Data supports the safety profile in the ASSERT clinical trial for Bylvay ... About PFIC and ALGS PFIC is a group of rare genetic disorders in which bile acids build up in the liver, causing damage, ...

This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...

Ipsen has shared positive three-year results for Iqirvo (elafibranor) in patients with the rare cholestatic liver disease ...

The livestock industry is increasingly interested in microencapsulated probiotics, which are more resistant to heat and bile ...

The FDA in 2016 granted accelerated approval to the FXR agonist as a second-line treatment for adults with PBC, either in ...